P450: PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS

• U. Pakulska,
• N. Angelosanto,
• M. Mikula,
• H. Nogai,
• R. Dudziak,
• C. Abboud,
• M. Obacz,
• K. Goller,
• M. Cybulska,
• M. Mazan,
• M. Kozakowska,
• T. Rzymski

Affiliations

U. Pakulska

1 R&D

N. Angelosanto

2 Clinical Department, Ryvu Therapeutics, Kraków

M. Mikula

3 Maria Skłodowska-Curie Institute - Cancer Center, Warsaw, Poland

H. Nogai

2 Clinical Department, Ryvu Therapeutics, Kraków

R. Dudziak

2 Clinical Department, Ryvu Therapeutics, Kraków

C. Abboud

4 Washington University School of Medicine in St. Louis, St Louis, United States of America

M. Obacz

1 R&D

K. Goller

1 R&D

M. Cybulska

3 Maria Skłodowska-Curie Institute - Cancer Center, Warsaw, Poland

M. Mazan

1 R&D

M. Kozakowska

1 R&D

T. Rzymski

1 R&D